The end of the coronavirus outbreak is looking more and more distant, but there at least comes some good news, in the form of more accurate diagnostics for 19-nCoV. And it’s a Nanjing company that we have to thank for this new tool in the coronavirus battle.
Launched on 27 January, the new coronavirus diagnostic kit has been developed by Nanjing Geneseeq. Compared with existing products, the new kit can detect the full viral genome sequence data of 19-nCoV with a higher accuracy than existing products.
According to a release by Dissemination Nanjing, the new product is at present going through emergency approval channels. It is hoped that sufficient kits can be prepared in the next 2 weeks so that they can be tested by 50,000 people.
- Coronavirus is NOT in Nanjing’s Water Supply
- A Letter from the Nanjing Foreign Affairs Office
- Wuhan Flights Arrive in Nanjing; Infected Patients to Tangshan
Who or what is Nanjing Geneseeq?
Founded by Shao Yang in 2008, Geneseeq is a next-generation sequencing (NGS) company, in the field of oncology precision medicine, based in Toronto, Canada.
Among other things, the firm provides genetic testing of rare diseases and cancer treatment solutions, based on the analysis of patients’ genes. Geneseeq translates this complex genomic information into meaningful decision-making tools for physicians, as such bringing precision medicine to cancer patients around the world.
The company’s laboratories are accredited by the College of American Pathologists (CAP) and are Clinical Laboratory Improvement Amendments (CLIA) certified.
- Gloves More Important than Masks in Virus Fight, Experts Agree
- Snow, Food & Schools Latest Challenges Amid Wuhan Virus Outbreak
- 19 n-CoV Patient Movements Released in Search for others
Geneseeq operates out of the MaRS Discovery District in Toronto that was founded in 2000. As a life science incubator, MaRS aims to commercialise publicly-funded medical research with the assistance of local private enterprises.
In Nanjing, Geneseeq settled their Chinese headquarters in Jiangbei New Area in 2013. The company has developed 400 technology optimisation processes and more than 800 research and cooperation projects, making them leaders the field. According to Bloomberg, this China division collaborates with over 350 cancer-specialty hospitals in 24 provinces across China, providing tests to approximately 20,000 patients.
Nanjing Geneseeq produces the new coronavirus diagnostic kit in a 9,000 square-metre clinical testing centre and manufacturing facility. Over 700 employees work therein.
